CTNNB1 and colorectal carcinoma: For instance, a peptide-based PROTAC could stably degrade beta-catenin and reduce Wnt signaling in organoids and mouse models of CRC, leading to tumor regression.571 With the advent of final clinical results from several phase II trials with the first PROTACs, and the ongoing advancement of PROTAC technology, it is expected that this novel class of drugs will also reshape the treatment of digestive cancers.